Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They get the flu in China? Could be a good year for oxygen condensors or whatever the heckfire $DHRM makes.
Stabbed at a few on the ask just to see if there was any life left in this thing. Need volume to get any size at this point.
On watch.
Dehaier one to watch.
Very low valued with significant new business expected for 2013. I think both the top and bottom lines will benefit greatly as will the stock price. Recent news is an indication things are already underway.
Very interesting looking chart. I will be taking a position on Monday.
I am. I think the company is selling shares to raise cash when it spikes up. Either this will be really good or really bad.
Dehaier Medical wins three-year supply contract, shares upat Reuters(Fri 11:56AM EDT)
InPlay: Dehaier Medical Systems wins 3 year procurement agreement from major Ukrainian medical equipment manufacturerBriefing.com(Fri 8:30AM EDT)
Are you still in this?
~ Monday! $DHRM ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $DHRM ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=DHRM&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=DHRM&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=DHRM
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=DHRM#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=DHRM+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=DHRM
Finviz: http://finviz.com/quote.ashx?t=DHRM
~ BusyStock: http://busystock.com/i.php?s=DHRM&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=DHRM >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
DHRM $1.72 Dehaier Medical Receives CE Mark Approval to Sell Sleep Diagnostic Devices and Air Compressors in Europe
PR NewswirePress Release: Dehaier Medical Systems Ltd. – Tue, Jan 10, 2012 7:00 AM EST
Companies:
* Dehaier Medical Systems Limited
RELATED QUOTES
Symbol Price Change
DHRM 1.72 +0.12
BEIJING , Jan. 10, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM - News) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced that it has received Conformite Europeenne (CE) certification for its sleep diagnostic devices and air compressors.
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )
Dehaier's DHR-998 sleep diagnostic device collects data on patients' respiration flow, pulse, oximetry, thoracoabdominal breathing, snoring and body position. Dehaier's air compressors are key supplemental devices for medical ventilators. The CE mark recognizes that the two products meet European Union (EU) health and safety standards and are approved for sale in the 27 member states of the EU and in the four members of the European Free Trade Association (EFTA).
Mr. Ping Chen , Chairman and Chief Executive Officer of Dehaier Medical stated, "We are thrilled to obtain the CE marking, which validates the high quality and manufacturing standards of Dehaier's innovative medical products. This lays a strong foundation for us to offer our sleep diagnostic devices and air compressors in the EU markets. Moreover, we intend to leverage this approval to further expand our distribution network in the European Union as well as other markets that rely on the CE mark process."
"We already ship our air compressor products to the Czech Republic , Hungary , Kyrgyzstan , Pakistan , Ukraine , and the Philippines . Following the CE approval, we will continue to seek more distribution and OEM opportunities worldwide," said Ms. Rayna Dong , Director of Dehaier's International Marketing. "The CE marking strengthens our ability to cooperate with potential distributors from EU countries. In the near term, we look to establish a strong footprint in the European market, which presents an enormous potential for Dehaier's medical equipment and homecare products."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD ( Italy ), Welch Allyn ( USA ), HEYER ( Germany ), Timesco (UK), eVent Medical (US) and JMS ( Japan ). Dehaier's technology is based on five patents and five software copyrights; additionally Dehaier has three pending patents, six pending software copyrights and proprietary technology. More information may be found at http://www.chinadhr.com.
DHRM $2.32 ; reported.
http://finance.yahoo.com/q/is?s=dhrm
looks like the person selling sub 3s had stopped, my purchase of 2.50 looking good, but my purchases 3.3-4.2 are work in progress, X=3.8s
dhrm has low float, so it can have large swings, on last Q earnings it was down over a buck, so I bought. Cannot exit large position quickly. So it can go lower. My approach, I will not buy at the lowest point and will sell before the highest. If next Q is a loss, oh boy
I'll just be watching for awhile,
as I'm cash poor right now. :(
Looks interesting though,
so I'm going to keep an eye on it.
I've only been actively investing for 2 1/2 years now.
I've made a lot of stupid mistakes...
but hey, it's a learning experience! :)
One thing I've noticed is that the less followers a stock has on iHub,
the better!
I found out when a pumper visited the yahoo cbai message board. My average is 3.96 (range of 3.4-4.3). I can wait, BV is around 5.5, if Q is better then last years Q, we go higher, but if lower still a profit then it becomes LT investment. My fear they want to grow quick and might do another offering, but long as my cost is below BV, and they make profits every Q I am okay.
all about next Q, if Q over Q info is good we go up. until then low float selling pressure from a shareholder.
got to love what the ceo makes in 2009 $28,400 and in 2010 $33,200. from their annual report. Item 11. Executive Compensation.
The following table shows the annual compensation paid by us for the years ended December 31, 2009 and 2010 to Ping Chen, our principal executive
officer. No other officer had a salary during either of the previous two years of more than $100,000.
Summary Compensation Table
We did not grant any equity awards in 2010 or 2009.
ceo pay tied to stock performance,
Named Executive Officers and Directors
Amount of Beneficial
Ownership
Percentage
Ownership
Ping Chen, Chief Executive Officer, Director 1,104,742 24.55 %
TIME TO LOAD UP BEFORE FDA APPROVAL COMING
UPDATE...
Dehaier is a fantastic Investment for the near and long term .The Company is profitable and cash flow positive and has very very low float of 1.5 million .DHRM awaiting several product approvals in USA and EU this Year .
Super low float + Upcoming approvals will bring this massive undervalued stock (P/E 4.8) to 20$++ in no time . Competiters like MR or CMED have a P/E of 20 !!!
DHRM is a real unknown gem IPO was last year at $8 . Time to load up the cheap shares before it gets discovered .GLTA
Dehaier Medical (DHRM)
Market Cap: 23 M
Cash : 6 M
Price : 5.30 $
Shares Out: 4.5 M ..( 3 M shares held by CEO+Insiders )
Low Float : 1.5 M
Fundamental Data
http://www.redchip.com/visibility/investor.asp?symbol=DHRM
Analyst Report from March 2011
http://www.dehaier.com.cn/UserFiles/DHRM_20110316_Update.pdf
Company Presentation March 2011
http://www.dehaier.com.cn/UserFiles/DHRM%20Investor%20Presentation_Mar%202011.pdf
CEO letter
http://finance.yahoo.com/news/Dehaier-Medical-Chairman-and-prnews-702965902.html?x=0&.v=1
International expansion into the US and Europe, where several of our homecare products are currently under review by the Food and Drug Administration (FDA) in the US and Conformite Europeenne (CE) in the European Union.
"2010 was a record year for Dehaier. We achieved strong growth across both our branded and third party medical devices, as well as our homecare products businesses, while positioning the Company for success in 2011 and beyond," said Mr. Ping Chen, CEO of Dehaier. "Key to our growth in 2010 was the continued advancement of our homecare products business, in which we achieved triple-digit gains for both the fourth quarter and full year. While the domestic market presents a compelling growth opportunity, international expansion is a critical element of our longer-term strategy and we are making meaningful progress in this regard, with several of our respiratory therapy homecare products currently pending regulatory approval in the United States and European Union. We believe that securing these approvals and rolling out our products in targeted international markets will provide another important catalyst for our business and help propel Dehaier to the next level of top- and bottom-line growth."
Dehaier is a fantastic Investment for the near and long term .The Company making real money and has very very low float of 1.5 million .DHRM awaiting several product approvals in USA and EU .
Super low float + FDA approvals = 20$++ in no time !!! GL
Dehaier Medical (DHRM)
Market Cap: 22.7 M
Cash : 6 M
Price : 5.04 $
Shares Out: 4.5 M ..( 3 M shares held by Insiders )
Fundamental Data
http://www.redchip.com/visibility/investor.asp?symbol=DHRM
Analyst Report from March 2011
http://www.dehaier.com.cn/UserFiles/DHRM_20110316_Update.pdf
Company Presentation March 2011
http://www.dehaier.com.cn/UserFiles/DHRM%20Investor%20Presentation_Mar%202011.pdf
CEO letter
http://finance.yahoo.com/news/Dehaier-Medical-Chairman-and-prnews-702965902.html?x=0&.v=1
International expansion into the US and Europe, where several of our homecare products are currently under review by the Food and Drug Administration (FDA) in the US and Conformite Europeenne (CE) in the European Union.
"2010 was a record year for Dehaier. We achieved strong growth across both our branded and third party medical devices, as well as our homecare products businesses, while positioning the Company for success in 2011 and beyond," said Mr. Ping Chen, CEO of Dehaier. "Key to our growth in 2010 was the continued advancement of our homecare products business, in which we achieved triple-digit gains for both the fourth quarter and full year. While the domestic market presents a compelling growth opportunity, international expansion is a critical element of our longer-term strategy and we are making meaningful progress in this regard, with several of our respiratory therapy homecare products currently pending regulatory approval in the United States and European Union. We believe that securing these approvals and rolling out our products in targeted international markets will provide another important catalyst for our business and help propel Dehaier to the next level of top- and bottom-line growth."
RedChip Visibility initial Report
Target Price: $9.00
Research Report
Enjoy
If Red Chip is involved I'm gone GLTA.. Hank
took a look at RedChip's compensation deal w/ DHRM, and fortunately DHRM is paying mostly cash for RedChip's services, with up to 20k 144 shares, so not too bad. I like DHRM's sector and growth.
DHRM agreed to pay RedChip Companies, Inc., a fee of $8,000 in cash per month and 10,000 shares of common stock under Rule 144 for twelve (12) months of these investor relations services, as well as 5,000 shares of common stock when the stock price reaches $6.00 and an additional 5,000 shares when the stock price reaches $7.50.
DHRM chart.
Institutional ownership
http://www.dailyfinance.com/company/dehaier-medical-systems-limited/dhrm/nas/institutional-ownership
Quick fundies
http://finviz.com/quote.ashx?t=dhrm&ty=c&ta=1&p=d
Filings
http://www.sec.gov/cgi-bin/browse-edgar?CIK=0001474627&action=getcompany
White_Tiger GEO Research
http://geoinvesting.com/companies/dhrm_dehaier_medical_systems/research
Rames List: China Healthcare Stocks, peer rank & valuation
http://fixyou.co.uk/screen_china_health.php
Lowtrade charting compilation
Momentum
TRIX - rate-of-change of smoothed moving average momo
StochRSI - overbought and oversold levels in RSI
momo
ROC - percent change
momo
Stochastic - over bought / over sold
momo
RSI - Average Gain / Average Loss
momo
WM%R - price close vs. range top /bottom
momo
----------------------------------------------------------
Trend
Aroon - close high /low
trend
DMI - price direction / ADX strength
trend
ATR - gap /small move - up down reversal
trend
Macd - +/- moving averages - direction & strength
trend
PPO - increasing / decreasing price
trend
-----------------------------------------------------------------
Volume
PVO - increasing / decreasing volume
volume
OBV - close above vs below totals
volume
Acc/Dist - ave close totals
volume
CMF - A/D strength divided by volume = pressure
volume
MFI - RSI volume-weighted
volume
TRIX & Aroon are trend indicators, not momo. As they are not oscilators but do present a stocks trend indication.
momentum/ trend indicators
RSI, & MFI; are oscillators. Good for support of trend.
MFI over bought over sold; 0 to 100, 50 is zero
RSI over bought over sold; o to 100, 50 is zero
The Money Flow Index (MFI) is a momentum indicator that is similar to the Relative Strength Index (RSI) in both interpretation and calculation. However, MFI is a more rigid indicator in that it is volume-weighted, and is therefore a good measure of the strength of money flowing in and out of a security
Volume indicators
OBV & CMF are volume indications good for pressure expected when a move starts.CMF shows pressure. 0 is zero + positive, - negative
Accumulation Distribution shows pressure, bottom is zero shows increasing and decreasing. Not +/-
OBV being less useful then AccumDist, AccumDist which is in turn less useful the CMF. Because AccumDist was an improvement to OBV and CMF an improvement to AccumDist. We should always put more weight on CMF.
Being in or being out vs.get in or get out: RSI and MFI
Like StochRSI, MFI shows 2 indications. Strength & overbought/oversold, because it graphs like an oscilator. It mainly relies on RSI for it's basis.
MFI uses volume with RSI to determine if more money is coming into a stock, then going out. And because the consensus is, price follows volume. You can judge entry/exit with the RSI position on the graph. MFI above 80 signals entry and below 20 exit.
While StochRSI signals Be In the stock or Be Out of the stock. MFI signals get In or Out.
It has a different focus then OBV, Acc/Dist, or CMF. While being in the volume group, because it uses volume in it's formula. It is mainly used for decision making, rather then support.
Like the Aroon, I disagree with where the books place this indicator. I would put it in the momo group, where you find other decision making indicators. They have the aroon in the momo group for decisions and I would place that in the trend group.
RECAP, MFI determines entry exit, or positive negative momentum. It's name and placement in the volume group is misleading. IMO
Summery
Choose 3 indicators, one trend, one momentum & one volume. Your watching for trend entry, will retail support your decision and how strong to expect any move you enter, will be. My choices to fulfill these are DMI, StochRSI and CMF.
sources
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45219382&txt2find=mfi
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45336616&txt2find=mfi
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=45337703&txt2find=mfi
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48320279&txt2find=mfi
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46259534&txt2find=mfi
drhm..
That's it.. No further interest.. Hire RedChip and you lose me.. Thought it was a nice company but now that Red Chip is there it will just be another POS from China with the PR getting stock to bury investors.. hank
Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
Date : 09/09/2010 @ 8:59AM
Source : PR Newswire
Stock
: Dehaier Medical Systems Limited (MM) (DHRM)
Quote : 6.31 1.25 (24.70%) @ 7:22AM
Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
Dehaier Medical Systems Limited (MM) Up over $1..$6.32 (NASDAQ:DHRM)
Intraday Stock Chart
Today : Thursday 9 September 2010
Click Here for more Dehaier Medical Systems Limited (MM) Charts.
Dehaier Medical Systems, Ltd. (Nasdaq: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing, and sale of medical devices and homecare medical products in China, announced today that it has retained RedChip Companies, Inc. to lead its public and investor relations programs.
DHRM A breath of fresh air
I've been adding since the 3,90's / low 4's
Current Ratio: 3,09
Debt Equity Ratio: 38%
Cash: 6,54M
Book Value: 13,89M
Gross Margin: 39%
Net Margin: 24%
Outstnding Shares: 4,5M
Market Cap: 20M
Estimated EPS for 2010 of 0,80 | PER of 5,50
I like the fact that they start trading through an IPO (at the worst time possible) and not trough a Stock reverse merger due to the present atmosphere regarding reverse merger stocks.
The stock lost around 70% since their IPO in April and at the present levels is way undervalued IMO.
The health Industry in China seems like a good place to be invested in IMHO:
In April 2009, the Chinese government implemented large-scale healthcare reform. The State Council allocated $123 billion as part of its New Medical Reform Plan. The plan contemplates the development of a universal healthcare system that will cover 90% of China’s population by the end of 2010 and will provide health coverage for all Chinese by 2020.
Specifically, within three years, the Chinese government aims to improve the urban healthcare system by rebuilding and restructuring 3,700 existing urban community health centers and 11,000 community health clinics. The plan will also accommodate the development of 2,400 new urban health centers. In effect, the plan de-emphasizes the prevalence of large, magnet facilities in favor of smaller, more accessible clinics.
Dehaier Medical Systems is an emerging company in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Timesco (UK), ResMed (Australia), Welch Allyn (USA), HEYER (Germany), Penlon (U.K) and JMS (Japan).
Company Overview
DHRM offers a broad range of approximately 30 products used in surgeries, hospital rooms and at home. DHRM also provides technical services and support to manufacturers and distributors. In recent years, DHRM has placed significant emphasis on respiratory and oxygen homecare products. Through the integration of technology, customer input and employee creativity, DHRM seeks to provide innovative, high quality and affordable products that improve the lives of people with sleep and respiratory disorders.
The company sells the majority of its products through a network of over 2,000 independent distributors. DHRM also employs 70 direct sales and sales support personnel selling directly to end users such as hospitals, clinics, government health bureaus and individual customers.
Dehaier leverages its network of relationships with healthcare facilities and has broadened its market reach by introducing new and more advanced products and new product lines that address different end-user populations.
Industry
DHRM has 155 employees including 20 in R&D. The company’s technology is based on two patents, five pending patents and proprietary technology. DHRM maintains a 5,400 square foot research and development center in its facility in Beijing. In addition, the company is cooperating with research institutes at two top ranked Chinese universities: Beijing University of Aeronautics & Astronautics and Beijing University of Technology and Science.
In addition, the plan is designed to dramatically improve medical services available for the 800 million rural poor in China. Through the plan, the Chinese government contemplates the development of clinics in every village and a hospital in every county in China by the end of 2011. If successfully implemented, the plan would result in at least 2,000 new county-level hospitals and 29,000 township hospitals and the upgrading of another 5,000 more.
Differentiators
Branded and Distributed Medical Devices
DHRM derives revenues from the sale of C-arm X-ray systems, anesthesia machines, patient monitors and general hospital products. The medical device segment is the company's largest business line of products and has the most extensive market penetration of its three product lines. DHRM anticipates continued revenue growth in its medical device product line as it further penetrates the market through developing and introducing advanced new product offerings.
Respiratory and Oxygen Homecare Products
DHRM derives revenues from sales of oxygen concentrators, CPAP devices, portable sleep screening and diagnostic devices and thermotherapy products. DHRM anticipates continued revenue growth from respiratory and oxygen homecare as new and more advanced products in this line are introduced. DHRM expects to increase distribution in China’s respiratory and oxygen homecare market as well as growing sales in international markets through use of distributors as well as through its direct sales platform.
Branded Technical Services
DHRM derives revenues from sales of air compressors and ventilator trolleys. DHRM anticipates continued growth in revenues from technical service products as they further penetrate this market by increasing the number of their distributors and maintaining a competitive pricing model.
Competitive Strengths
Established brand and market position in China’s medical products and respiratory and oxygen homecare industries
Established distribution, sales and service network throughout China
Strong research and development capabilities
Established relationships with foreign medical device manufacturers
Established relationships with hospital customers
Dedicated customer support and service
Recent News
8/16/10-Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to $1.14 Million; EPS $0.278/12/10-Dehaier Medical Systems Schedules Second Quarter 2010 Earnings Release and Conference Call8/11/10-Dehaier Medical Systems To Exhibit in International Medical Products Tradeshow FIME 2010 in Miami, Florida7/13/10-Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line7/06/10-Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010
Risk Factors
Uncertain trading volume following IPO
China’s healthcare-related government policies
Acceptance level of DHRM products among hospitals and other healthcare facilities
Ability to attract and retain distributors, key customers and direct sales force
China’s competitive environment
The Outlook
DHRM is positioned to benefit from the surging growth of expenditures on medical products in China and the growing demand for domestic medical products. A recent article published by the Wharton School (Univ. of Pennsylvania) suggests that China’s medical products market will reach $28 billion by 2014. This market was valued at $12.14 billion in 2008, representing roughly one-eighth of China’s overall healthcare market.
China’s medical products market is projected to grow faster than the global medical market. China is already the third largest medical products market in the world behind the United States and Japan. Within five to seven years it is expected to surpass Japan to become the world’s second largest medical products market. Market growth rates for 2009 are projected at 11.2%.
DHRM’s strategy is to strengthen its position as one of China’s leaders in developing, assembling and marketing respiratory and oxygen homecare products and to develop a presence in select foreign markets including Europe and America.
DRHM.. $5.00
Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27
Company Continues to Expand Marketing Strategies
BEIJING, Aug. 16 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today reported financial results for its second quarter 2010 ended June 30, 2010.
Q2 2010 Financial Highlights
-- Revenue for the second quarter ended June 30, 2010 increased 46% to
$4.83 million from $3.31 million in the same quarter a year ago
reflecting the increased acceptance of the company&;s products among
hospitals and other healthcare facilities. Expanded product lines also
contributed to the revenue growth.
-- Gross profit increased 46% to $1.92 million for Q2 FY&;10 from $1.31
million in Q2 FY&;09.
-- Gross margin for the second quarter ended March 31, 2010 remained
constant at 40%, the same as the second quarter in 2009.
-- Operating income rose 52.76% to $1.36 million in Q2 FY&;10 compared with
$0.89 million in Q2 FY&;09 primarily due to the increased revenues.
-- Net income attributable to Dehaier for the second quarter ended June 30,
2010 increased 59% to $1.14 million, compared to $0.72 million for the
same period of 2009.
-- Earnings per diluted share in Q2 FY&;10 was $0.27, compared to $0.24 per
diluted share in Q2 FY&;09.
Six Months Highlights
-- Revenue for the first six months of 2010 increased by 28% to $7.47
million from $5.83 million in the first six months of 2009.
-- Gross profit increased 29% to $2.89 million from $2.25 million in the
same period of 2009.
-- Gross margin for the first six months ended June 30, 2010 remained
constant at 39%, which is the same as that of the first six months in
2009.
-- Operating income rose 49% to $2.0 million from $1.35 million in the
same period of 2009.
-- Net income attributable to Dehaier for the first six months increased
58% to $1.66 million, compared to $1.05 million for the same period of
2009.
-- Earnings per diluted share in H1 FY&;10 was $0.46, compared to $0.35 per
diluted share in H1 FY&;09.
Liquidity and Capital Resources
The company&;s cash balance on June 30, 2010 was approximately $6.54 million. On June 30, 2010 Dehaier had short-term debt of $1,474,610 in the form of a short-term bank loan due in June 2011. The company had no long-term debt. Working capital was $17,559,244, which the company said would be adequate to meet anticipated cash needs and sustain current operations for at least 12 months.
Management Comments
Dehaier CEO Mr. Ping Chen said, "The second quarter of 2010 was an exciting period for our rapidly growing company. We recorded another quarter of excellent financial results and our stock began trading on the Nasdaq Capital Market with our successful initial public offering ("IPO"), which closed on April 22, 2010. We sold 1,500,000 shares that produced net proceeds of $9,944,207.
"This has provided us with sufficient working capital to expand our marketing efforts in order to grow our revenues in China and internationally.
"The increase in revenues reflected increased acceptance of our products among hospitals and other healthcare facilities as many of our end users such as hospitals became repeat customers when they needed new medical equipment. The increase in revenue was also due to Dehaier&;s growing line of product offerings.
"We signed several exclusive distribution agreements this quarter with international firms Penlon, HEYER and Welch Allyn to expand our product lines. Sales of products from these companies are already contributing to revenue growth.
"We are targeting the addition of four to eight new product offerings per year. We anticipate these new products will include distributed products as well as products that are developed or acquired by Dehaier. We have designated 25 percent of the IPO proceeds for product research and development. Another 20 percent of the IPO proceeds have been budgeted for potential acquisitions, clearly showing our focus on building a pipeline of products to introduce to our customers. We will be concentrating on products that enhance our capability to serve the respiratory and oxygen homecare markets.
"Underscoring the important competitive advantage we are achieving with our proprietary home oxygen therapy products is our previously-announced new contract with Beijing C&D Co. to purchase Dehaier oxygen-chip units.
"In addition to increasing sales of our fast-growing Dehaier brand homecare medical products, we are building new revenue streams by adding to our product line offerings through complementary acquisitions, such as the emergency ventilator product line we purchased from Beijing Qiumanshi Technology Co., as announced last month. That acquisition included the production technology as well as the complete proprietary intellectual property.
"With the marketing capital provided by our IPO, we plan to open new customer experience centers ("CECs") to strengthen our market presence throughout China. These CECs give our potential customers an opportunity to experience our products first-hand in an environment similar to the environment in which they will use the products, either in a home or in a healthcare facility. Our initial CEC is already operational in Beijing and we anticipate opening three new CECs in the third quarter and up to nine CECs during the fourth quarter, so that we will operate CECs in twelve cities at the end of 2010. Our plan to open CECs in provincial capitals and big cities throughout China is a key part of our strategy for growing our high-margin homecare medical product sales.
"We have participated in several medical exhibitions and tradeshows in China and abroad to network and build relationships and alliances as we further build our distribution network in China and internationally.
"Our business outlook continues to be very favorable. We are excited to bring our growth story to the financial community, and were very pleased to participate recently in the Global Hunter investment conference in San Francisco. We remain comfortable with our previously announced earnings per share target for 2010 of $0.80," Mr. Chen said.
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier&;s technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .
Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .
For more information, please contact:
Investor contact:
Hawk Associates
Julie Marshall or Grace Huang
Tel: +1-305-451-1888
Email: dehaier@hawkassociates.com
DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE
CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, December 31,
2010 2009
US$ US$
(unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents 6,540,009 1,151,721
Accounts receivable, less allowance for
doubtful accounts of $77,783 and
$102,939 8,867,002 6,891,291
Other receivables 2,765,248 1,499,111
Prepayment and other current assets 4,611,990 1,691,387
Inventory, net 3,165,490 2,326,126
Total Current Assets 25,949,739 13,559,636
Property and equipment, net 2,803,429 2,862,625
Tax receivable 1,926,290 1,362,372
Total assets 30,679,458 17,784,633
LIABILITIES AND SHAREHOLDERS&; EQUITY
Short-term borrowings 1,474,610 1,464,770
Accounts payable 16,675 93,770
Advances from customers 92,606 174,253
Accrued expenses and other current
liabilities 263,076 336,412
Tax payable 6,111,966 4,993,387
Warranty obligation 179,956 178,755
Warrants Liability 251,606 --
Due to officer -- 3,861
Total current liabilities 8,390,495 7,245,208
Commitments and contingency -- --
Shareholders&; equity
Common stock, $0.002731 par value,
18,307,038 shares authorized,
4,500,000 and 3,000,000 shares
issued and outstanding at June 30, 2010
and December 31, 2009, respectively 12,290 8,193
Additional paid in capital 13,137,085 3,196,974
Retained earnings 6,958,377 5,298,742
Accumulated other comprehensive income 900,285 773,127
Total Dehaier Medical Systems Limited
shareholders&; equity 21,008,037 9,277,036
Non-controlling interest 1,280,926 1,262,389
Total shareholders&; equity 22,288,963 10,539,425
Total liabilities and shareholders&; equity 30,679,458 17,784,633
DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the six months ended For the three months ended
June 30, June 30,
2010 2009 2010 2009
US$ US$ US$ US$
Revenue 7,471,951 5,834,018 4,830,862 3,309,734
Costs of revenue (4,577,795) (3,586,713) (2,911,077) (1,999,225)
Gross profit 2,894,156 2,247,305 1,919,785 1,310,509
Service income 181,506 196,328 88,439 97,093
Service expenses (68,346) (74,981) (40,325) (37,713)
General and
administrative expense (520,409) (628,581) (297,024) (291,015)
Selling expense (482,810) (391,694) (314,959) (191,265)
Operating Income 2,004,097 1,348,377 1,355,916 887,609
Financial expense
(including interest
expense of $26,728,
$43,932, $7,900 and
$15,567) (54,686) (45,082) (35,360) (16,126)
Change in fair value
of warrants liability 18,394 -- 18,394 --
Income before provision
for income taxes and
non-controlling
interest 1,967,805 1,303,295 1,338,950 871,483
Provision for income
tax (298,180) (226,450) (203,297) (145,838)
Net income 1,669,625 1,076,845 1,135,653 725,645
Non-Controlling interest
in (income) loss (9,991) (23,720) 3,770 (10,376)
Net income
attributable to
Dehaier Medical
Systems Limited 1,659,634 1,053,125 1,139,423 715,269
Earnings per share
-Basic 0.46 0.56 0.27 0.38
-Diluted 0.46 0.35 0.27 0.24
-- -- -- --
Weighted average
number of common
shares used in
computation
-Basic 3,575,000 1,891,930 4,150,000 1,891,930
-Diluted 3,632,500 3,000,000 4,265,000 3,000,000
DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the six months ended
June 30,
2010 2009
US$ US$
Operating Activities
Net income 1,669,625 1,076,845
Adjustment to reconcile net income to net
cash provided by (used in)operating
activities -- --
Depreciation and amortization 172,314 139,012
Recovery of doubtful accounts (25,680) --
Provision for (recovery
of)inventory obsolescence (1,922) 52,989
Change in Warrants Liability 18,394 --
Changes in assets and liabilities
Increase in accounts receivable (1,950,032) (1,593,441)
Decrease (increase) in prepayments and
other current assets (2,920,603) 938,541
Increase in other receivable (1,266,137) (107,157)
Increase in inventory (837,443) (1,392,611)
Increase in tax receivable (563,918) (462,317)
(Decrease) increase in accounts payable (77,095) 677,283
Decrease in advances
from customers (81,647) (43,896)
(Decrease) increase in accrued expenses
and other current liabilities 159,880 (10,911)
Increase in tax payable 1,118,579 780,699
Net cash provided by (used in) operating
activities (4,585,685) 55,036
Investing Activities
Capital expenditures and other
additions (94,397) (18,696)
Proceeds from (advances to)
related parties (3,861) 5,656
-- --
Net cash used in investing activities (98,258) (13,040)
Financing Activities
Proceeds from initial public offering 9,944,207 --
Net cash provided by financing activities 9,944,207 --
Effect of exchange rate fluctuations on
cash and cash equivalents 128,024 10,818
Net increase in cash and cash
equivalents 5,388,288 52,814
Cash and cash equivalents at
beginning of period 1,151,721 282,603
Cash and cash equivalents at end
of period 6,540,009 335,417
Supplemental cash flow information
Income tax paid 24,604 12,823
Interest paid 26,728 43,932
SOURCE Dehaier Medical Systems Ltd.
DHLR.. $4.06.. Earnings Schedule..
Dehaier Medical Systems Schedules Second Quarter 2010 Earnings Release and
Conference Call
BEIJING, Aug 12, 2010 /PRNewswire via COMTEX/ -- Dehaier Medical Systems Ltd.
(DHRM), an emerging leader in the development, assembly, marketing and sale of
medical devices and homecare medical products in China, announced today that it
will release its financial results for the second quarter of 2010 on Monday,
August 16, 2010. A copy of the earnings release will be available at
http://www.hawkassociates.com .
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )
Dehaier will host an earnings conference call on Tuesday, August 17, 2010 at 9:00
a.m. Eastern Time (9:00 pm Beijing time on August 17). The call will cover the
company's second quarter 2010 results and a question-and-answer session will
follow.
To participate, call U.S. toll free number 1-888-549-7735 approximately 10
minutes before the call. International callers, please dial 1-480-629-9858. The
conference ID number is 4349036. A live and archived webcast of the call will be
available at http://viavid.net/dce.aspx?sid=000079A8 . Both an MP3 file one hour
after the call and a transcript 24 hours after the call will be available. These
will be archived for 90 days via http://www.hawkassociates.com .
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly,
marketing and sale of medical products in China, including respiratory and oxygen
homecare medical products. The company develops and assembles its own branded
products from third party components. The company also distributes products
designed and manufactured by other companies including medical devices and
respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA),
Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan).
Dehaier's technology is based on two patents, five pending patents and
proprietary technology. More information may be found at http://www.chinadhr.com
.
Information for investors, including an investment profile about Dehaier is
available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor
kit including press releases, current price quotes, stock charts and other
valuable information for investors is available at http://www.hawkassociates.com
.
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to uncertainties and
risks including, but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of competition and
pricing, government regulation, and other risks contained in reports filed by the
company with the Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on behalf of the
company, are expressly qualified by the cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
For more information, please contact
Investor contact:
Hawk Associates
Julie Marshall or Grace Huang
Tel:+1-305-451-1888
Email: dehaier@hawkassociates.com
SOURCE Dehaier Medical Systems Ltd.
Copyright (C) 2010 PR Newswire. All rights reserved
DHRM.. $4.31.. To Exhibit
Dehaier Medical Systems to Exhibit in International Medical Products Tradeshow FIME 2010 in Miami, Florida
Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced today that it is participating in the International FIME 2010 Show for medical manufacturers. The company will exhibit its Homecare Medical Products at Booth 125 at the Miami Beach Convention Center in Miami, Florida for three days, August 11 through August 13, 2010. Dehaier CEO Ping Chen will also be available to meet with members of the Chinese and international medical community who are gathered to attend the comprehensive medical tradeshow.
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20100422/CNTH001LOGO )
Mr. Chen said, "We are thrilled to be participating this year in the FIME Show, which is one of the largest medical manufacturing tradeshows for the international medical community. FIME draws medical distributors, hospital purchasing agents as well as clinicians and physicians from the U.S. and over 110 countries around the world including China. The event provides Dehaier significant exposure to the Chinese and international medical community in attendance, as well as providing networking for distribution and alliance opportunities with manufacturers of medical technology, medical products and supplies, medical equipment and services."
Additional information about FIME 2010 is available online at http://www.fimeshow.com/ .
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier's technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .
Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
Investor Contact:
Hawk Associates
Julie Marshall or Grace Huang
Tel: +1-305-451-1888
Email: dehaier@hawkassociates.com
DHRM.. $4.80
Acquires Emergency Ventilator
Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line
PR Newswire - Jul 13 at 09:30
Company Symbols: NASDAQ-SMALL:DHRM
BEIJING, July 13 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced today that it has acquired an emergency ventilator product line (QS-100A series) from Beijing Qiumanshi Technology Co., Ltd. The acquisition includes the production technology and complete proprietary intellectual property.
(Logo: http://www.newscom.com/cgi-bin/prnh/20100422/CNTH001LOGO )
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )
The QS-100A series is a multi-functional emergency, portable synchronized ventilator. It is pneumatic-driven and gas-controlled, requiring no other power supply. Because of its compact size and low weight, it can be effectively used on the scene in accident cases and during patient transportation.
Dehaier CEO Ping Chen said, "This acquisition complements our ventilator product line. Dehaier already has well-established ventilator products for home use and hospital use. Our latest product now allows us to provide portable ventilator products for use at a medical emergency site as well as during ambulance transport to the hospital."
Dehaier estimates the annual demand for emergency ventilators in China is approximately RMB150 million (US$22 million). The company expects production capacity to reach 2,000 units per year, suggesting an annual product revenue of RMB 20 million (US$2.9 million).
Chen added, "This acquisition qualifies Dehaier to participate in the 11th five-year rural cooperative medical service development project for emergency medical products, and expands our company&;s respiratory care product range. We are really pleased to add a portable ventilator that can be carried by rescue units for emergency use. We intend to continue to broaden our product lines to better serve our growing customer base."
About Beijing Qiumanshi Technology Co., Ltd.
Beijing Qiumanshi Technology Co., Ltd. is an operating entity that combines designing, developing, manufacturing, distributing and service providing. Its products have been widely used in China and exported to Brunei and Africa. Company website: http://www.bjqms.com.cn/cpxx.asp .
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier&;s technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .
Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
Investor contact:
Hawk Associates
Julie Marshall or Frank Hawkins
Tel: +1-305-451-1888
Email: dehaier@hawkassociates.com
SOURCE Dehaier Medical Systems Ltd.
DHRM.. $6.45 Would be a great buy in the $4's
Dehaier Medical Systems Reaffirms Earnings Estimate of $0.80 EPS for FY 2010
PR Newswire - Jul 06 at 16:02
Company Symbols: NASDAQ-SMALL:DHRM
DHRM.. $6.45
BEIJING, China, July 6 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today reaffirmed the company&;s earlier earnings estimate of $0.80 EPS for fiscal year 2010.
(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20100422/CNTH001LOGO )
At a bell ringing ceremony at Nasdaq, CEO Ping Chen said, "In our S-1 filing, when we went public, we set a target for our company to earn $0.80 per share in 2010. Based on the current tone of business and our preliminary unaudited results from the second quarter, which ended last week, we remain confident in this projection. Due to the nature of our business and its seasonality, the majority of revenues are received in the third and fourth quarters."
The remarks were made as Mr. Chen rang the closing bell at Nasdaq and began a week-long series of meetings with investors and members of the financial community in New York.
Mr. Chen said, "Our business has grown through innovation and the development of our own medical device products as well as selling, distributing and servicing medical products of foreign companies including several American companies. China&;s medical industry is on the edge of profound change and rapid growth through the increasing introduction of modern medical technology to supplement China&;s historic reliance on traditional medicine. Our company is already a leader in respiratory and oxygen home care equipment in China and in the years ahead we intend to expand our product line and grow our business in China as well as abroad."
About Dehaier Medical Systems Ltd.
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier&;s technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .
Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .
Forward-looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
Investor contact:
Hawk Associates
Julie Marshall or Frank Hawkins
Tel: +1-305-451-1888
Email: dehaier@hawkassociates.com
SOURCE Dehaier Medical Systems Ltd.
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
86
|
Created
|
07/07/10
|
Type
|
Free
|
Moderators |
Dehaier Medical Systems is an emerging leader in the development, assembly, marketing and sale of medical products in China, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded products from third party components. The company also distributes products designed and manufactured by other companies including medical devices and respiratory and oxygen homecare products from IMD (Italy), Welch Allyn (USA), Penlon (UK), HEYER (Germany), Timesco (UK), ResMed (Australia) and JMS (Japan). Dehaier&;s technology is based on two patents, five pending patents and proprietary technology. More information may be found at http://www.chinadhr.com .
Information for investors, including an investment profile about Dehaier is available at http://www.hawkassociates.com/profile/dhrm.cfm . An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors is available at http://www.hawkassociates.com .
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |